Biomarker in Diabetes Market by type (Prediabetes, Type 2 Diabetes and others) by Application (Traditional Biomarkers, Novel Biomarker, Inflammatory Biomarker and Others) by End User (Research Institutions, Pharmaceutical Companies, Biopharmaceutical Companies, Hospitals and Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 - 2029
Industry Trends
Global biomarker in diabetes market was valued at US$ 321.65 billion in 2020 and is expected to reach US$ 782.01 billion by 2029, growing at a CAGR of 18.4% over the forecast period. Diabetes is one of the major lifestyle diseases and a leading cause of cardiovascular diseases. It is necessary to identify the potential biomarkers associated with diabetes for the early detection of the disease and its proper management. Elevated blood pressure, low HDL cholesterol, and elevated triglycerides are some of the common biomarkers of diabetes, adiponectin, C-reactive protein (CRP), ferritin, interleukin-2 receptor A being the other counterparts. Such a factor is expected to aid the overall market over the next eight years.
Type Insights
The type insights are segregated into prediabetes, Type 2 diabetes and others. Type 2 diabetes is usually diagnosed using the glycated hemoglobin (A1C) test. This blood test indicates the average blood sugar level for the past two to three months. Leptin appeared to be the hub of the network, along with five other biomarkers that differed significantly between case and noncase subjects, including total adiponectin, high-molecular-weight adiponectin, CRP, HbA1c, and IGF binding protein 2 (IGFBP-2). sOB-R was another important node in the network, and also had connections with five other biomarkers, including insulin, HbA1c, total adiponectin, high-molecular-weight adiponectin, and E-selectin. Such a factor is expected to aid the overall market over the next eight years.
Biomarker Type Insights
Novel Biomarkers is expected to witness the highest compound annual growth rate over the forecast period. The newly identified novel biomarkers include interleukin-1 receptor antagonist (IL-1RA), insulin growth factor binding protein-2 (IGFBP-2), soluble E-selectin (sE selectin), decorin, adiponectin, and high-density lipoprotein cholesterol (HDL-C).
Regional Insights
North America accounted for the largest share in market; this growth can be attributed to rising demand from consumers in the United States. The United States region captured more than 85% in 2020 and is expected to continue the same trend over the forecast period. The United States Food and Drug Administration encourage the integration of biomarkers in medical product development and approval, to facilitate the monitoring of FDA-regulated products, and their appropriate use in clinical practice. Biomarkers promise to reduce stagnation and foster innovation in the development of new medical products and precision medicine categories. HbA1c is the most commonly used biomarker to diagnose prediabetes and diabetes. Hemoglobin A1c (HbA1c) can be considered as a biomarker for the presence and severity of hyperglycemia, implying diabetes or pre-diabetes, or, over time, as a “biomarker for a risk factor”, that is, hyperglycemia as a risk factor for diabetic retinopathy, nephropathy, and other vascular diseases of diabetes
Biomarker in Diabetes Market Revenue & Forecast, (US$ Million), 2021 – 2029
Competitive Landscape
The report provides both, qualitative and quantitative research on biomarker in diabetes market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
The major players operating in the biomarker in diabetes market include Patia Biopharma partnered with Precision Diabetes, Virta Health, F. Hoffmann-La Roche Ltd and other market participants.
Biomarker in Diabetes Market:
By Type
- Prediabetes
- Type 2 diabetes
- Others
By Biomarker Type
- Traditional Biomarkers
- Novel Biomarker
- Inflammatory Biomarker
- Others
By End User
- Research Institutions
- Pharmaceutical Companies
- Biopharmaceutical Companies
- Hospitals
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1.
Market
Segmentation
1.2.
Years
Considered
1.2.1.
Historic
Years: 2015 - 2019
1.2.2.
Base
Year: 2020
1.2.3.
Forecast
Years: 2021 – 2029
2.
Key
Target Audiences
3.
Research
Methodology
3.1.
Primary
Research
3.1.1.
Research
Questionnaire
3.1.2.
Global
Percentage Breakdown
3.1.3.
Primary
Interviews: Key Opinion Leaders (KOLs)
3.2.
Secondary
Research
3.2.1.
Paid
Databases
3.2.2.
Secondary
Sources
3.3.
Market
Size Estimates
3.3.1.
Top-Down
Approach
3.3.2.
Bottom-Up
Approach
3.4.
Data
Triangulation Methodology
3.5.
Research
Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Biomarker in diabetes Market
6.
Market
Synopsis: Biomarker in diabetes Market
7.
Biomarker
in diabetes Market Analysis: Qualitative Perspective
7.1.
Introduction
7.1.1.
Product
Definition
7.1.2.
Industry
Development
7.2.
Market
Dynamics
7.2.1.
Drivers
7.2.2.
Restraints
7.2.3.
Opportunities
7.2.4.
Challenges
7.3.
Trends
in Biomarker in diabetes Market
7.4.
Market
Determinants Radar Chart
7.5.
Macro-Economic
and Micro-Economic Indicators: Biomarker in diabetes Market
7.6.
Industry
Gross Margin Overview
7.7.
Porter’s
Five Force Analysis
7.8.
Impact
of Covid-19 on Biomarker in diabetes Market
8.
Global
Biomarker in diabetes Market Analysis and Forecasts, 2021 – 2029
8.1.
Overview
8.1.1.
Global
Biomarker in diabetes Market Revenue (US$ Mn)
8.2.
Global
Biomarker in diabetes Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1.
Prediabetes
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.1.3.
Market
Forecast, 2021 - 2029
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2015 - 2020
8.2.1.5.1.2. Market Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2020
8.2.1.5.2.2. Market Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2020
8.2.1.5.3.2. Market Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2020
8.2.1.5.4.2. Market Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2015 - 2020
8.2.1.5.5.2. Market Forecast, 2021 - 2029
8.2.2.
Type 2
diabetes
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.2.3.
Market
Forecast, 2021 - 2029
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2015 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2015 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.2.3.
Others
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.3.3.
Market
Forecast, 2021 - 2029
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2015 - 2020
8.2.3.5.1.2. Market Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2020
8.2.3.5.2.2. Market Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2020
8.2.3.5.3.2. Market Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2020
8.2.3.5.4.2. Market Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2015 - 2020
8.2.3.5.5.2. Market Forecast, 2021 - 2029
8.3.
Key
Segment for Channeling Investments
8.3.1.
By Type
9.
Global
Biomarker in diabetes Market Analysis and Forecasts, 2021 – 2029
9.1.
Overview
9.2.
Global
Biomarker in diabetes Market Revenue (US$ Mn) and Forecasts, By Biomarker Type
9.2.1.
Traditional
Biomarkers
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.1.3.
Market
Forecast, 2021 - 2029
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2015 - 2020
9.2.1.5.1.2. Market Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2020
9.2.1.5.2.2. Market Forecast, 2021 - 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2020
9.2.1.5.3.2. Market Forecast, 2021 - 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2020
9.2.1.5.4.2. Market Forecast, 2021 - 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2015 - 2020
9.2.1.5.5.2. Market Forecast, 2021 - 2029
9.2.2.
Novel
Biomarker
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.2.3.
Market
Forecast, 2021 - 2029
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2015 - 2020
9.2.2.5.1.2. Market Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2020
9.2.2.5.2.2. Market Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2020
9.2.2.5.3.2. Market Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2020
9.2.2.5.4.2. Market Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2015 - 2020
9.2.2.5.5.2. Market Forecast, 2021 - 2029
9.2.3.
Inflammatory
Biomarker
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.3.3.
Market
Forecast, 2021 - 2029
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market Estimation, 2015 - 2020
9.2.3.5.1.2. Market Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2020
9.2.3.5.2.2. Market Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2020
9.2.3.5.3.2. Market Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2020
9.2.3.5.4.2. Market Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market Estimation, 2015 - 2020
9.2.3.5.5.2. Market Forecast, 2021 - 2029
9.2.4.
Others
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.4.3.
Market
Forecast, 2021 - 2029
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market Estimation, 2015 - 2020
9.2.4.5.1.2. Market Forecast, 2021 - 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2020
9.2.4.5.2.2. Market Forecast, 2021 - 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2020
9.2.4.5.3.2. Market Forecast, 2021 - 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2020
9.2.4.5.4.2. Market Forecast, 2021 - 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market Estimation, 2015 - 2020
9.2.4.5.5.2. Market Forecast, 2021 - 2029
9.3.
Key
Segment for Channeling Investments
9.3.1.
By
Biomarker Type
10. Global Biomarker in diabetes Market Analysis
and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
10.2.1. Research Institutions
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 -
2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2020
10.2.1.5.1.2. Market Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2020
10.2.1.5.2.2. Market Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2020
10.2.1.5.3.2. Market Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2020
10.2.1.5.4.2. Market Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2020
10.2.1.5.5.2. Market Forecast, 2021 - 2029
10.2.2. Pharmaceutical Companies
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2020
10.2.2.5.1.2. Market Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2020
10.2.2.5.2.2. Market Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2020
10.2.2.5.3.2. Market Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2020
10.2.2.5.4.2. Market Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2020
10.2.2.5.5.2. Market Forecast, 2021 - 2029
10.2.3. Biopharmaceutical Companies
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 -
2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2020
10.2.3.5.1.2. Market Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2020
10.2.3.5.2.2. Market Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2020
10.2.3.5.3.2. Market Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2020
10.2.3.5.4.2. Market Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2020
10.2.3.5.5.2. Market Forecast, 2021 - 2029
10.2.4. Hospitals
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 -
2020
10.2.4.3. Market Forecast, 2021 - 2029
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2015 - 2020
10.2.4.5.1.2. Market Forecast, 2021 - 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2020
10.2.4.5.2.2. Market Forecast, 2021 - 2029
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2020
10.2.4.5.3.2. Market Forecast, 2021 - 2029
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2020
10.2.4.5.4.2. Market Forecast, 2021 - 2029
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2015 - 2020
10.2.4.5.5.2. Market Forecast, 2021 - 2029
10.2.5. Others
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 -
2020
10.2.5.3. Market Forecast, 2021 - 2029
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market Estimation, 2015 - 2020
10.2.5.5.1.2. Market Forecast, 2021 - 2029
10.2.5.5.2. Europe
10.2.5.5.2.1. Market Estimation, 2015 - 2020
10.2.5.5.2.2. Market Forecast, 2021 - 2029
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market Estimation, 2015 - 2020
10.2.5.5.3.2. Market Forecast, 2021 - 2029
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market Estimation, 2015 - 2020
10.2.5.5.4.2. Market Forecast, 2021 - 2029
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market Estimation, 2015 - 2020
10.2.5.5.5.2. Market Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By End User
11. North America Biomarker in diabetes Market
Analysis and Forecasts, 2021 - 2029
11.1. Overview
11.1.1. North America Biomarker in diabetes Market
Revenue (US$ Mn)
11.2. North America Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
11.2.1. Prediabetes
11.2.2. Type 2 diabetes
11.2.3. Others
11.3. North America Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
11.3.1. Traditional Biomarkers
11.3.2. Novel Biomarker
11.3.3. Inflammatory Biomarker
11.3.4. Others
11.4. North America Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
11.4.1. Research Institutions
11.4.2. Pharmaceutical Companies
11.4.3. Biopharmaceutical Companies
11.4.4. Hospitals
11.4.5. Others
11.5. North America Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Biomarker in diabetes Market Revenue (US$
Mn) and Forecasts, By Type
11.5.1.1.1. Prediabetes
11.5.1.1.2. Type 2 diabetes
11.5.1.1.3. Others
11.5.1.2. U.S Biomarker in diabetes Market Revenue (US$
Mn) and Forecasts, By Biomarker Type
11.5.1.2.1. Traditional Biomarkers
11.5.1.2.2. Novel Biomarker
11.5.1.2.3. Inflammatory Biomarker
11.5.1.2.4. Others
11.5.1.3. U.S Biomarker in diabetes Market Revenue (US$
Mn) and Forecasts, By End User
11.5.1.3.1. Research Institutions
11.5.1.3.2. Pharmaceutical Companies
11.5.1.3.3. Biopharmaceutical Companies
11.5.1.3.4. Hospitals
11.5.1.3.5. Others
11.5.2. Canada
11.5.2.1. Canada Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
11.5.2.1.1. Prediabetes
11.5.2.1.2. Type 2 diabetes
11.5.2.1.3. Others
11.5.2.2. Canada Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
11.5.2.2.1. Traditional Biomarkers
11.5.2.2.2. Novel Biomarker
11.5.2.2.3. Inflammatory Biomarker
11.5.2.2.4. Others
11.5.2.3. Canada Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
11.5.2.3.1. Research Institutions
11.5.2.3.2. Pharmaceutical Companies
11.5.2.3.3. Biopharmaceutical Companies
11.5.2.3.4. Hospitals
11.5.2.3.5. Others
11.5.3. Mexico
11.5.3.1. Mexico Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
11.5.3.1.1. Prediabetes
11.5.3.1.2. Type 2 diabetes
11.5.3.1.3. Others
11.5.3.2. Mexico Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
11.5.3.2.1. Traditional Biomarkers
11.5.3.2.2. Novel Biomarker
11.5.3.2.3. Inflammatory Biomarker
11.5.3.2.4. Others
11.5.3.3. Mexico Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
11.5.3.3.1. Research Institutions
11.5.3.3.2. Pharmaceutical Companies
11.5.3.3.3. Biopharmaceutical Companies
11.5.3.3.4. Hospitals
11.5.3.3.5. Others
11.5.4. Rest of North America
11.5.4.1. Rest of North America Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By Type
11.5.4.1.1. Prediabetes
11.5.4.1.2. Type 2 diabetes
11.5.4.1.3. Others
11.5.4.2. Rest of North America Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By Biomarker Type
11.5.4.2.1. Traditional Biomarkers
11.5.4.2.2. Novel Biomarker
11.5.4.2.3. Inflammatory Biomarker
11.5.4.2.4. Others
11.5.4.3. Rest of North America Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By End User
11.5.4.3.1. Research Institutions
11.5.4.3.2. Pharmaceutical Companies
11.5.4.3.3. Biopharmaceutical Companies
11.5.4.3.4. Hospitals
11.5.4.3.5. Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Type
11.6.3. By Biomarker Type
11.6.4. By End User
12. Europe Biomarker in diabetes Market Analysis
and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. Europe Biomarker in diabetes Market Revenue
(US$ Mn)
12.2. Europe Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
12.2.1. Prediabetes
12.2.2. Type 2 diabetes
12.2.3. Others
12.3. Europe Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
12.3.1. Traditional Biomarkers
12.3.2. Novel Biomarker
12.3.3. Inflammatory Biomarker
12.3.4. Others
12.4. Europe Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
12.4.1. Research Institutions
12.4.2. Pharmaceutical Companies
12.4.3. Biopharmaceutical Companies
12.4.4. Hospitals
12.4.5. Others
12.5. Europe Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.1.1.1. Prediabetes
12.5.1.1.2. Type 2 diabetes
12.5.1.1.3. Others
12.5.1.2. France Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
12.5.1.2.1. Traditional Biomarkers
12.5.1.2.2. Novel Biomarker
12.5.1.2.3. Inflammatory Biomarker
12.5.1.2.4. Others
12.5.1.3. France Biomarker in diabetes Market Revenue (US$
Mn) and Forecasts, By End User
12.5.1.3.1. Research Institutions
12.5.1.3.2. Pharmaceutical Companies
12.5.1.3.3. Biopharmaceutical Companies
12.5.1.3.4. Hospitals
12.5.1.3.5. Others
12.5.2. The UK
12.5.2.1. The UK Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.2.1.1. Prediabetes
12.5.2.1.2. Type 2 diabetes
12.5.2.1.3. Others
12.5.2.2. The UK Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
12.5.2.2.1. Traditional Biomarkers
12.5.2.2.2. Novel Biomarker
12.5.2.2.3. Inflammatory Biomarker
12.5.2.2.4. Others
12.5.2.3. The UK Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
12.5.2.3.1. Research Institutions
12.5.2.3.2. Pharmaceutical Companies
12.5.2.3.3. Biopharmaceutical Companies
12.5.2.3.4. Hospitals
12.5.2.3.5. Others
12.5.3. Spain
12.5.3.1. Spain Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.3.1.1. Prediabetes
12.5.3.1.2. Type 2 diabetes
12.5.3.1.3. Others
12.5.3.2. Spain Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
12.5.3.2.1. Traditional Biomarkers
12.5.3.2.2. Novel Biomarker
12.5.3.2.3. Inflammatory Biomarker
12.5.3.2.4. Others
12.5.3.3. Spain Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
12.5.3.3.1. Research Institutions
12.5.3.3.2. Pharmaceutical Companies
12.5.3.3.3. Biopharmaceutical Companies
12.5.3.3.4. Hospitals
12.5.3.3.5. Others
12.5.4. Germany
12.5.4.1. Germany Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.4.1.1. Prediabetes
12.5.4.1.2. Type 2 diabetes
12.5.4.1.3. Others
12.5.4.2. Germany Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
12.5.4.2.1. Traditional Biomarkers
12.5.4.2.2. Novel Biomarker
12.5.4.2.3. Inflammatory Biomarker
12.5.4.2.4. Others
12.5.4.3. Germany Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
12.5.4.3.1. Research Institutions
12.5.4.3.2. Pharmaceutical Companies
12.5.4.3.3. Biopharmaceutical Companies
12.5.4.3.4. Hospitals
12.5.4.3.5. Others
12.5.5. Italy
12.5.5.1. Italy Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.5.1.1. Prediabetes
12.5.5.1.2. Type 2 diabetes
12.5.5.1.3. Others
12.5.5.2. Italy Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
12.5.5.2.1. Traditional Biomarkers
12.5.5.2.2. Novel Biomarker
12.5.5.2.3. Inflammatory Biomarker
12.5.5.2.4. Others
12.5.5.3. Italy Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
12.5.5.3.1. Research Institutions
12.5.5.3.2. Pharmaceutical Companies
12.5.5.3.3. Biopharmaceutical Companies
12.5.5.3.4. Hospitals
12.5.5.3.5. Others
12.5.6. Nordic Countries
12.5.6.1. Nordic Countries Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
12.5.6.1.1. Prediabetes
12.5.6.1.2. Type 2 diabetes
12.5.6.1.3. Others
12.5.6.2. Nordic Countries Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
12.5.6.2.1. Traditional Biomarkers
12.5.6.2.2. Novel Biomarker
12.5.6.2.3. Inflammatory Biomarker
12.5.6.2.4. Others
12.5.6.3. Nordic Countries Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
12.5.6.3.1. Research Institutions
12.5.6.3.2. Pharmaceutical Companies
12.5.6.3.3. Biopharmaceutical Companies
12.5.6.3.4. Hospitals
12.5.6.3.5. Others
12.5.6.4. Nordic Countries Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1. Benelux Union Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
12.5.7.1.1. Prediabetes
12.5.7.1.2. Type 2 diabetes
12.5.7.1.3. Others
12.5.7.2. Benelux Union Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
12.5.7.2.1. Traditional Biomarkers
12.5.7.2.2. Novel Biomarker
12.5.7.2.3. Inflammatory Biomarker
12.5.7.2.4. Others
12.5.7.3. Benelux Union Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
12.5.7.3.1. Research Institutions
12.5.7.3.2. Pharmaceutical Companies
12.5.7.3.3. Biopharmaceutical Companies
12.5.7.3.4. Hospitals
12.5.7.3.5. Others
12.5.7.4. Benelux Union Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1. Rest of Europe Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
12.5.8.1.1. Prediabetes
12.5.8.1.2. Type 2 diabetes
12.5.8.1.3. Others
12.5.8.2. Rest of Europe Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
12.5.8.2.1. Traditional Biomarkers
12.5.8.2.2. Novel Biomarker
12.5.8.2.3. Inflammatory Biomarker
12.5.8.2.4. Others
12.5.8.3. Rest of Europe Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
12.5.8.3.1. Research Institutions
12.5.8.3.2. Pharmaceutical Companies
12.5.8.3.3. Biopharmaceutical Companies
12.5.8.3.4. Hospitals
12.5.8.3.5. Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Type
12.6.3. By Biomarker Type
12.6.4. By End User
13. Asia Pacific Biomarker in diabetes Market
Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Asia Pacific Biomarker in diabetes Market
Revenue (US$ Mn)
13.2. Asia Pacific Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Prediabetes
13.2.2. Type 2 diabetes
13.2.3. Others
13.3. Asia Pacific Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
13.3.1. Traditional Biomarkers
13.3.2. Novel Biomarker
13.3.3. Inflammatory Biomarker
13.3.4. Others
13.4. Asia Pacific Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
13.4.1. Research Institutions
13.4.2. Pharmaceutical Companies
13.4.3. Biopharmaceutical Companies
13.4.4. Hospitals
13.4.5. Others
13.5. Asia Pacific Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.1.1.1. Prediabetes
13.5.1.1.2. Type 2 diabetes
13.5.1.1.3. Others
13.5.1.2. China Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
13.5.1.2.1. Traditional Biomarkers
13.5.1.2.2. Novel Biomarker
13.5.1.2.3. Inflammatory Biomarker
13.5.1.2.4. Others
13.5.1.3. China Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
13.5.1.3.1. Research Institutions
13.5.1.3.2. Pharmaceutical Companies
13.5.1.3.3. Biopharmaceutical Companies
13.5.1.3.4. Hospitals
13.5.1.3.5. Others
13.5.2. Japan
13.5.2.1. Japan Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.2.1.1. Prediabetes
13.5.2.1.2. Type 2 diabetes
13.5.2.1.3. Others
13.5.2.2. Japan Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
13.5.2.2.1. Traditional Biomarkers
13.5.2.2.2. Novel Biomarker
13.5.2.2.3. Inflammatory Biomarker
13.5.2.2.4. Others
13.5.2.3. Japan Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
13.5.2.3.1. Research Institutions
13.5.2.3.2. Pharmaceutical Companies
13.5.2.3.3. Biopharmaceutical Companies
13.5.2.3.4. Hospitals
13.5.2.3.5. Others
13.5.3. India
13.5.3.1. India Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.3.1.1. Prediabetes
13.5.3.1.2. Type 2 diabetes
13.5.3.1.3. Others
13.5.3.2. India Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
13.5.3.2.1. Traditional Biomarkers
13.5.3.2.2. Novel Biomarker
13.5.3.2.3. Inflammatory Biomarker
13.5.3.2.4. Others
13.5.3.3. India Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
13.5.3.3.1. Research Institutions
13.5.3.3.2. Pharmaceutical Companies
13.5.3.3.3. Biopharmaceutical Companies
13.5.3.3.4. Hospitals
13.5.3.3.5. Others
13.5.4. New Zealand
13.5.4.1. New Zealand Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
13.5.4.1.1. Prediabetes
13.5.4.1.2. Type 2 diabetes
13.5.4.1.3. Others
13.5.4.2. New Zealand Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
13.5.4.2.1. Traditional Biomarkers
13.5.4.2.2. Novel Biomarker
13.5.4.2.3. Inflammatory Biomarker
13.5.4.2.4. Others
13.5.4.3. New Zealand Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
13.5.4.3.1. Research Institutions
13.5.4.3.2. Pharmaceutical Companies
13.5.4.3.3. Biopharmaceutical Companies
13.5.4.3.4. Hospitals
13.5.4.3.5. Others
13.5.5. Australia
13.5.5.1. Australia Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
13.5.5.1.1. Prediabetes
13.5.5.1.2. Type 2 diabetes
13.5.5.1.3. Others
13.5.5.2. Australia Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
13.5.5.2.1. Traditional Biomarkers
13.5.5.2.2. Novel Biomarker
13.5.5.2.3. Inflammatory Biomarker
13.5.5.2.4. Others
13.5.5.3. Australia Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
13.5.5.3.1. Research Institutions
13.5.5.3.2. Pharmaceutical Companies
13.5.5.3.3. Biopharmaceutical Companies
13.5.5.3.4. Hospitals
13.5.5.3.5. Others
13.5.6. South Korea
13.5.6.1. South Korea Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
13.5.6.1.1. Prediabetes
13.5.6.1.2. Type 2 diabetes
13.5.6.1.3. Others
13.5.6.2. South Korea Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
13.5.6.2.1. Traditional Biomarkers
13.5.6.2.2. Novel Biomarker
13.5.6.2.3. Inflammatory Biomarker
13.5.6.2.4. Others
13.5.6.3. South Korea Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
13.5.6.3.1. Research Institutions
13.5.6.3.2. Pharmaceutical Companies
13.5.6.3.3. Biopharmaceutical Companies
13.5.6.3.4. Hospitals
13.5.6.3.5. Others
13.5.7. Southeast Asia
13.5.7.1. Southeast Asia Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
13.5.7.1.1. Prediabetes
13.5.7.1.2. Type 2 diabetes
13.5.7.1.3. Others
13.5.7.2. Southeast Asia Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
13.5.7.2.1. Traditional Biomarkers
13.5.7.2.2. Novel Biomarker
13.5.7.2.3. Inflammatory Biomarker
13.5.7.2.4. Others
13.5.7.3. Southeast Asia Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
13.5.7.3.1. Research Institutions
13.5.7.3.2. Pharmaceutical Companies
13.5.7.3.3. Biopharmaceutical Companies
13.5.7.3.4. Hospitals
13.5.7.3.5. Others
13.5.7.4. Southeast Asia Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1. Rest of Asia Pacific Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By Type
13.5.8.1.1. Prediabetes
13.5.8.1.2. Type 2 diabetes
13.5.8.1.3. Others
13.5.8.2. Rest of Asia Pacific Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By Biomarker Type
13.5.8.2.1. Traditional Biomarkers
13.5.8.2.2. Novel Biomarker
13.5.8.2.3. Inflammatory Biomarker
13.5.8.2.4. Others
13.5.8.3. Rest of Asia Pacific Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By End User
13.5.8.3.1. Research Institutions
13.5.8.3.2. Pharmaceutical Companies
13.5.8.3.3. Biopharmaceutical Companies
13.5.8.3.4. Hospitals
13.5.8.3.5. Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Type
13.6.3. By Biomarker Type
13.6.4. By End User
14. Middle East and Africa Biomarker in diabetes
Market Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Middle East and Africa Biomarker in diabetes
Market Revenue (US$ Mn)
14.2. Middle East and Africa Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Prediabetes
14.2.2. Type 2 diabetes
14.2.3. Others
14.3. Middle East and Africa Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By Biomarker Type
14.3.1. Traditional Biomarkers
14.3.2. Novel Biomarker
14.3.3. Inflammatory Biomarker
14.3.4. Others
14.4. Middle East and Africa Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By End User
14.4.1. Research Institutions
14.4.2. Pharmaceutical Companies
14.4.3. Biopharmaceutical Companies
14.4.4. Hospitals
14.4.5. Others
14.5. Middle East and Africa Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1. Saudi Arabia Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
14.5.1.1.1. Prediabetes
14.5.1.1.2. Type 2 diabetes
14.5.1.1.3. Others
14.5.1.2. Saudi Arabia Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
14.5.1.2.1. Traditional Biomarkers
14.5.1.2.2. Novel Biomarker
14.5.1.2.3. Inflammatory Biomarker
14.5.1.2.4. Others
14.5.1.3. Saudi Arabia Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
14.5.1.3.1. Research Institutions
14.5.1.3.2. Pharmaceutical Companies
14.5.1.3.3. Biopharmaceutical Companies
14.5.1.3.4. Hospitals
14.5.1.3.5. Others
14.5.2. UAE
14.5.2.1. UAE Biomarker in diabetes Market Revenue (US$
Mn) and Forecasts, By Type
14.5.2.1.1. Prediabetes
14.5.2.1.2. Type 2 diabetes
14.5.2.1.3. Others
14.5.2.2. UAE Biomarker in diabetes Market Revenue (US$
Mn) and Forecasts, By Biomarker Type
14.5.2.2.1. Traditional Biomarkers
14.5.2.2.2. Novel Biomarker
14.5.2.2.3. Inflammatory Biomarker
14.5.2.2.4. Others
14.5.2.3. UAE Biomarker in diabetes Market Revenue (US$
Mn) and Forecasts, By End User
14.5.2.3.1. Research Institutions
14.5.2.3.2. Pharmaceutical Companies
14.5.2.3.3. Biopharmaceutical Companies
14.5.2.3.4. Hospitals
14.5.2.3.5. Others
14.5.3. Egypt
14.5.3.1. Egypt Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
14.5.3.1.1. Prediabetes
14.5.3.1.2. Type 2 diabetes
14.5.3.1.3. Others
14.5.3.2. Egypt Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
14.5.3.2.1. Traditional Biomarkers
14.5.3.2.2. Novel Biomarker
14.5.3.2.3. Inflammatory Biomarker
14.5.3.2.4. Others
14.5.3.3. Egypt Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
14.5.3.3.1. Research Institutions
14.5.3.3.2. Pharmaceutical Companies
14.5.3.3.3. Biopharmaceutical Companies
14.5.3.3.4. Hospitals
14.5.3.3.5. Others
14.5.4. Kuwait
14.5.4.1. Kuwait Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
14.5.4.1.1. Prediabetes
14.5.4.1.2. Type 2 diabetes
14.5.4.1.3. Others
14.5.4.2. Kuwait Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
14.5.4.2.1. Traditional Biomarkers
14.5.4.2.2. Novel Biomarker
14.5.4.2.3. Inflammatory Biomarker
14.5.4.2.4. Others
14.5.4.3. Kuwait Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
14.5.4.3.1. Research Institutions
14.5.4.3.2. Pharmaceutical Companies
14.5.4.3.3. Biopharmaceutical Companies
14.5.4.3.4. Hospitals
14.5.4.3.5. Others
14.5.5. South Africa
14.5.5.1. South Africa Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
14.5.5.1.1. Prediabetes
14.5.5.1.2. Type 2 diabetes
14.5.5.1.3. Others
14.5.5.2. South Africa Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
14.5.5.2.1. Traditional Biomarkers
14.5.5.2.2. Novel Biomarker
14.5.5.2.3. Inflammatory Biomarker
14.5.5.2.4. Others
14.5.5.3. South Africa Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
14.5.5.3.1. Research Institutions
14.5.5.3.2. Pharmaceutical Companies
14.5.5.3.3. Biopharmaceutical Companies
14.5.5.3.4. Hospitals
14.5.5.3.5. Others
14.5.6. Rest of Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Biomarker in
diabetes Market Revenue (US$ Mn) and Forecasts, By Type
14.5.6.1.1. Prediabetes
14.5.6.1.2. Type 2 diabetes
14.5.6.1.3. Others
14.5.6.2. Rest of Middle East & Africa Biomarker in
diabetes Market Revenue (US$ Mn) and Forecasts, By Biomarker Type
14.5.6.2.1. Traditional Biomarkers
14.5.6.2.2. Novel Biomarker
14.5.6.2.3. Inflammatory Biomarker
14.5.6.2.4. Others
14.5.6.3. Rest of Middle East & Africa Biomarker in
diabetes Market Revenue (US$ Mn) and Forecasts, By End User
14.5.6.3.1. Research Institutions
14.5.6.3.2. Pharmaceutical Companies
14.5.6.3.3. Biopharmaceutical Companies
14.5.6.3.4. Hospitals
14.5.6.3.5. Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Type
14.6.3. By Biomarker Type
14.6.4. By End User
15. Latin America Biomarker in diabetes Market
Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Latin America Biomarker in diabetes Market
Revenue (US$ Mn)
15.2. Latin America Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Prediabetes
15.2.2. Type 2 diabetes
15.2.3. Others
15.3. Latin America Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
15.3.1. Traditional Biomarkers
15.3.2. Novel Biomarker
15.3.3. Inflammatory Biomarker
15.3.4. Others
15.4. Latin America Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
15.4.1. Research Institutions
15.4.2. Pharmaceutical Companies
15.4.3. Biopharmaceutical Companies
15.4.4. Hospitals
15.4.5. Others
15.5. Latin America Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Type
15.5.1.1.1. Prediabetes
15.5.1.1.2. Type 2 diabetes
15.5.1.1.3. Others
15.5.1.2. Brazil Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By Biomarker Type
15.5.1.2.1. Traditional Biomarkers
15.5.1.2.2. Novel Biomarker
15.5.1.2.3. Inflammatory Biomarker
15.5.1.2.4. Others
15.5.1.3. Brazil Biomarker in diabetes Market Revenue
(US$ Mn) and Forecasts, By End User
15.5.1.3.1. Research Institutions
15.5.1.3.2. Pharmaceutical Companies
15.5.1.3.3. Biopharmaceutical Companies
15.5.1.3.4. Hospitals
15.5.1.3.5. Others
15.5.2. Argentina
15.5.2.1. Argentina Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Type
15.5.2.1.1. Prediabetes
15.5.2.1.2. Type 2 diabetes
15.5.2.1.3. Others
15.5.2.2. Argentina Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By Biomarker Type
15.5.2.2.1. Traditional Biomarkers
15.5.2.2.2. Novel Biomarker
15.5.2.2.3. Inflammatory Biomarker
15.5.2.2.4. Others
15.5.2.3. Argentina Biomarker in diabetes Market
Revenue (US$ Mn) and Forecasts, By End User
15.5.2.3.1. Research Institutions
15.5.2.3.2. Pharmaceutical Companies
15.5.2.3.3. Biopharmaceutical Companies
15.5.2.3.4. Hospitals
15.5.2.3.5. Others
15.5.3. Rest of Latin America
15.5.3.1. Rest of Latin America Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By Type
15.5.3.1.1. Prediabetes
15.5.3.1.2. Type 2 diabetes
15.5.3.1.3. Others
15.5.3.2. Rest of Latin America Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By Biomarker Type
15.5.3.2.1. Traditional Biomarkers
15.5.3.2.2. Novel Biomarker
15.5.3.2.3. Inflammatory Biomarker
15.5.3.2.4. Others
15.5.3.3. Rest of Latin America Biomarker in diabetes
Market Revenue (US$ Mn) and Forecasts, By End User
15.5.3.3.1. Research Institutions
15.5.3.3.2. Pharmaceutical Companies
15.5.3.3.3. Biopharmaceutical Companies
15.5.3.3.4. Hospitals
15.5.3.3.5. Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Type
15.6.3. By Biomarker Type
15.6.4. By End User
16. Competitive Benchmarking
16.1. Market Share Analysis, 2020
16.2. Global Presence and Growth Strategies
16.2.1. Mergers and Acquisitions
16.2.2. Product Launches
16.2.3. Investments Trends
16.2.4. R&D Initiatives
17. Player Profiles
17.1. Patia Biopharma partnered with Precision
Diabetes
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. Virta Health
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. F. Hoffmann-La Roche Ltd
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. Other Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
